NeoGenomics, Inc. (NEO) to Post Q3 2019 Earnings of $0.06 Per Share, First Analysis Forecasts

NeoGenomics, Inc. (NASDAQ:NEO) – Equities research analysts at First Analysis issued their Q3 2019 EPS estimates for shares of NeoGenomics in a research note issued to investors on Wednesday, October 31st. First Analysis analyst R. Department forecasts that the medical research company will earn $0.06 per share for the quarter. First Analysis currently has a “Buy” rating and a $16.00 target price on the stock.

Other analysts have also issued reports about the stock. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 3rd. Raymond James raised their price target on shares of NeoGenomics from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Craig Hallum raised their price target on shares of NeoGenomics from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday. Leerink Swann initiated coverage on shares of NeoGenomics in a research report on Tuesday, August 21st. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research lowered shares of NeoGenomics from a “hold” rating to a “sell” rating in a research report on Thursday, July 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. NeoGenomics has a consensus rating of “Buy” and an average target price of $19.70.



NASDAQ NEO opened at $18.44 on Thursday. The company has a current ratio of 1.74, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of 307.33 and a beta of 0.42. NeoGenomics has a 52-week low of $7.08 and a 52-week high of $18.88.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The firm had revenue of $69.10 million for the quarter, compared to the consensus estimate of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 3.15%. The business’s quarterly revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 EPS.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the 2nd quarter valued at about $171,000. AMP Capital Investors Ltd acquired a new stake in shares of NeoGenomics during the 2nd quarter valued at about $178,000. PNC Financial Services Group Inc. acquired a new stake in shares of NeoGenomics during the 2nd quarter valued at about $272,000. WINTON GROUP Ltd acquired a new stake in shares of NeoGenomics during the 1st quarter valued at about $338,000. Finally, Sei Investments Co. boosted its position in shares of NeoGenomics by 44.8% during the 1st quarter. Sei Investments Co. now owns 49,115 shares of the medical research company’s stock valued at $401,000 after acquiring an additional 15,192 shares in the last quarter. Institutional investors own 81.54% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Story: What are the Benefits of Index Funds?

Earnings History and Estimates for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply